INSULIN GLULISINE (HMR1964)

DRUG4 trials

Sponsors

Sanofi

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes, Type IType 2 Diabetes Mellitus

Phase 3

12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.

CompletedNCT00046150

SanofiDiabetes, Type I

Start: 2002-05-31End: 2002-12-31Updated: 2008-06-19

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

CompletedNCT03529123

SanofiType 2 Diabetes Mellitus

Start: 2018-06-19End: 2019-11-25Updated: 2022-04-25

Phase 4

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus

CompletedNCT00964574

SanofiDiabetes Mellitus, Type 1

Start: 2009-07-31End: 2010-07-31Updated: 2012-07-17

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

CompletedNCT01234597

SanofiDiabetes Mellitus, Type 2

Start: 2012-12-31End: 2015-04-30Updated: 2016-07-13